Table 1 Baseline Characteristics of Patients in FAS (n = 43)

From: Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

Characteristic

No. of patient (%)

Age, years

Median age (IQR)

65 (60–69)

Age group

 <65 years

21 (48.8)

 ≥65 years

22 (51.2)

Sex

 Male

40 (93.0)

 Female

3 (7.0)

ECOG performance status

 0

0 (0.0)

 1

43 (100.0)

Smoking status

 Never

2 (4.7)

 Current or Former

41 (95.3)

AJCC stage8th

 IIIc

6 (14.0)

 IVa

21 (48.8)

 IVb

16 (37.2)

LDH at baseline

 ≤ULN

26 (60.5)

 >ULN

17 (39.5)

Brain metastasis

 Yes

2 (4.7)

 No

41 (95.3)

Liver metastasis

 Yes

9 (20.9)

 No

34 (79.1)

Bone metastasis

 Yes

13 (30.2)

 No

30 (69.8)

PD-L1

 <1%

31 (72.1)

 ≥1%

7 (16.3)

 Unknown

5 (11.6)

  1. Data cutoff: April 1, 2024
  2. Data are number of patients (% of patients)
  3. FAS full analysis set, IQR interquartile range, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, LDH lactate dehydrogenase, ULN upper limit of normal
Back to article page